life science investing Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
life science investing Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
life science investing Interim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
life science investing Ambrx Announces NovoCodex's Dosing of First Patient with ARX305, Ambrx's Investigational Antibody Drug Conjugate Targeting CD70
life science investing Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update
life science investing Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
life science investing Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project
Terra Clean Energy Corp. Announces Agreement to Earn 100% Interest in 75 Past Producing Uranium Claims on The San Rafael Swell, Utah, United States
Silver47 Announces Closing of $23 Million Brokered LIFE Financing, Including Full Exercise of the Over-Allotment Option
